Table 2.

Seroconversion rates as measured by anti-Vi IgG ELISA.

All Ages:
Response	Time point		Vi-DT Group		Placebo Group		P-value
Seroconversion ratea(95% CI)	First Dose	Day 0	228	–	57	–	–
		Week 4	228	100.0 (98.34, 100.0)	57	7.02 (2.76, 16.70)	<0.0001
Age Strata1: 6 to less than 9 m
Response	Time point		Vi-DT Group		Placebo Group		P-value
Seroconversion ratea(95% CI)	First Dose	Day 0	76	–	19	–	–
		Week 4	76	100.0 (95.19, 100.0)	19	10.53 (2.94, 31.39)	–
Age Strata2: 9–12 m
Response	Time point		Vi-DT Group		Placebo Group		P-value
Seroconversion ratea(95% CI)	First Dose	Day 0	76	–	19	–	–
		Week 4	76	100.0 (95.19, 100.0)	19	5.26 (0.94, 24.64)	–
Age Strata3: 13–23 m
Response	Time point		Vi-DT Group		Placebo Group		P-value
Seroconversion ratea(95% CI)	First Dose	Day 0	76	–	19	–	–
		Week 4	76	100.0 (95.19, 100.0)	19	5.26 (0.94, 24.64)	–

^aProportion of participants who had 4-fold rise in titers compared to baseline (Day 0, Week 0) to post dose.